CCL4 Stimulates Cell Migration in Human Osteosarcoma via the mir-3927-3p/Integrin αvβ3 Axis.
Hsiao-Chi TsaiYan-You LaiHsuan-Chih HsuYi-Chin FongMing-Yu LienChih-Hsin TangPublished in: International journal of molecular sciences (2021)
Osteosarcoma is the most common type of primary malignant bone cancer, and it is associated with high rates of pulmonary metastasis. Integrin αvβ3 is critical for osteosarcoma cell migratory and invasive abilities. Chemokine (C-C motif) ligand 4 (CCL4) has diverse effects on different cancer cells through its interaction with its specific receptor, C-C chemokine receptor type 5 (CCR5). Analysis of mRNA expression in human osteosarcoma tissue identified upregulated levels of CCL4, integrin αv and β3 expression. Similarly, an analysis of records from the Gene Expression Omnibus (GEO) dataset showed that CCL4 was upregulated in human osteosarcoma tissue. Importantly, the expression of both CCL4 and integrin αvβ3 correlated positively with osteosarcoma clinical stages and lung metastasis. Analysis of osteosarcoma cell lines identified that CCL4 promotes integrin αvβ3 expression and cell migration by activating the focal adhesion kinase (FAK), protein kinase B (AKT), and hypoxia inducible factor 1 subunit alpha (HIF-1α) signaling pathways, which can downregulate microRNA-3927-3p expression. Pharmacological inhibition of CCR5 by maraviroc (MVC) prevented increases in integrin αvβ3 expression and cell migration. This study is the first to implicate CCL4 as a potential target in the treatment of metastatic osteosarcoma.
Keyphrases
- cell migration
- poor prognosis
- endothelial cells
- liver fibrosis
- liver injury
- gene expression
- protein kinase
- binding protein
- signaling pathway
- stem cells
- drug induced
- long non coding rna
- pluripotent stem cells
- induced pluripotent stem cells
- risk assessment
- pulmonary hypertension
- bone marrow
- bone mineral density
- oxidative stress
- immune response
- cystic fibrosis
- body composition
- combination therapy
- escherichia coli
- candida albicans
- postmenopausal women